Browse GSS

Summary
SymbolGSS
Nameglutathione synthetase
Aliases GSHS; HEL-S-64p; HEL-S-88n; GSH synthetase; GSH-S; epididymis secretory sperm binding protein Li 64p; epidid ......
Chromosomal Location20q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF03917 Eukaryotic glutathione synthase
PF03199 Eukaryotic glutathione synthase
Function

-

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0006520 cellular amino acid metabolic process
GO:0006575 cellular modified amino acid metabolic process
GO:0006749 glutathione metabolic process
GO:0006750 glutathione biosynthetic process
GO:0006790 sulfur compound metabolic process
GO:0006979 response to oxidative stress
GO:0007568 aging
GO:0009410 response to xenobiotic stimulus
GO:0009991 response to extracellular stimulus
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0019184 nonribosomal peptide biosynthetic process
GO:0031667 response to nutrient levels
GO:0034612 response to tumor necrosis factor
GO:0042398 cellular modified amino acid biosynthetic process
GO:0043200 response to amino acid
GO:0044272 sulfur compound biosynthetic process
GO:0046686 response to cadmium ion
Molecular Function GO:0000287 magnesium ion binding
GO:0004363 glutathione synthase activity
GO:0016594 glycine binding
GO:0016597 amino acid binding
GO:0016874 ligase activity
GO:0016879 ligase activity, forming carbon-nitrogen bonds
GO:0016881 acid-amino acid ligase activity
GO:0031406 carboxylic acid binding
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0043168 anion binding
GO:0043295 glutathione binding
GO:0072341 modified amino acid binding
GO:1900750 oligopeptide binding
GO:1901681 sulfur compound binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00270 Cysteine and methionine metabolism
hsa00480 Glutathione metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-211859: Biological oxidations
R-HSA-156590: Glutathione conjugation
R-HSA-174403: Glutathione synthesis and recycling
R-HSA-1430728: Metabolism
R-HSA-156580: Phase II conjugation
Summary
SymbolGSS
Nameglutathione synthetase
Aliases GSHS; HEL-S-64p; HEL-S-88n; GSH synthetase; GSH-S; epididymis secretory sperm binding protein Li 64p; epidid ......
Chromosomal Location20q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GSS and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolGSS
Nameglutathione synthetase
Aliases GSHS; HEL-S-64p; HEL-S-88n; GSH synthetase; GSH-S; epididymis secretory sperm binding protein Li 64p; epidid ......
Chromosomal Location20q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GSS in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.79; FDR: 0.04170 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.74; FDR: 0.04110 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolGSS
Nameglutathione synthetase
Aliases GSHS; HEL-S-64p; HEL-S-88n; GSH synthetase; GSH-S; epididymis secretory sperm binding protein Li 64p; epidid ......
Chromosomal Location20q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GSS in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0350.892
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1190.96
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1420.932
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2310.45
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0860.96
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4190.854
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2660.475
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3250.834
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2080.904
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0970.957
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0280.991
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0980.159
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GSS in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGSS
Nameglutathione synthetase
Aliases GSHS; HEL-S-64p; HEL-S-88n; GSH synthetase; GSH-S; epididymis secretory sperm binding protein Li 64p; epidid ......
Chromosomal Location20q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GSS. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGSS
Nameglutathione synthetase
Aliases GSHS; HEL-S-64p; HEL-S-88n; GSH synthetase; GSH-S; epididymis secretory sperm binding protein Li 64p; epidid ......
Chromosomal Location20q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GSS. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GSS.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGSS
Nameglutathione synthetase
Aliases GSHS; HEL-S-64p; HEL-S-88n; GSH synthetase; GSH-S; epididymis secretory sperm binding protein Li 64p; epidid ......
Chromosomal Location20q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GSS. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGSS
Nameglutathione synthetase
Aliases GSHS; HEL-S-64p; HEL-S-88n; GSH synthetase; GSH-S; epididymis secretory sperm binding protein Li 64p; epidid ......
Chromosomal Location20q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GSS expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGSS
Nameglutathione synthetase
Aliases GSHS; HEL-S-64p; HEL-S-88n; GSH synthetase; GSH-S; epididymis secretory sperm binding protein Li 64p; epidid ......
Chromosomal Location20q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GSS and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGSS
Nameglutathione synthetase
Aliases GSHS; HEL-S-64p; HEL-S-88n; GSH synthetase; GSH-S; epididymis secretory sperm binding protein Li 64p; epidid ......
Chromosomal Location20q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GSS collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting GSS.
ID Name Drug Type Targets #Targets
DB00143GlutathioneSmall MoleculeAKR1B1, CYP3A4, ESD, GGT1, GLO1, GLRX, GLRX2, GPX1, GPX2, GPX3, GP ......41
DB00145GlycineSmall MoleculeAGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLR ......30
DB00151L-CysteineSmall MoleculeCARS, CARS2, CBS, CDO1, CSAD, CTH, GCLC, GCLM, GOT1, GSS, MGMT, NF ......13
DB03408gamma-GlutamylcysteineSmall MoleculeGSS1
DB04395Phosphoaminophosphonic Acid-Adenylate EsterSmall MoleculeACTA1, CCT3, CFTR, CSNK2A1, DAPK1, DTYMK, EPHA2, EPHB2, GALK1, GSK ......26
DB06151AcetylcysteineSmall MoleculeACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, SLC ......10
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141